Honey East, MD
Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1932132495
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $513,613 of the $721,113 with a category attached, or 71.2%. 60 manufacturers reported payments, led by Corcept Therapeutics at 44.3% of the total. Among endocrinology, diabetes & metabolism clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,932 payments — averaging $373.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$319K
- Amgen$164K
- Boehringer Ingelheim$133K
- Lilly USA, LLC$89K
- Biomarin Pharmaceutical Inc.$2K
- Novo Nordisk$2K
- plus $12K from 54 others
Across 24 payments — averaging $7608.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$135K
- Corcept Therapeutics$47K
What the payments were for
- Consulting fees$110,56215%
- Speaking & faculty fees$513,61371%
- Travel & lodging$64,8009%
- Food & beverage$31,9934%
- Education$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$721,113 in reported general payments places this provider in the 95th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 15 | $355,663 |
| OzempicSemaglutide | 164 | $224,898 |
| Repatha SureclickEvolocumab | 154 | $171,359 |
| MounjaroTirzepatide | 151 | $164,975 |
| JardianceEmpagliflozin | 104 | $102,677 |
| TrulicityDulaglutide | 67 | $75,368 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $34,300 |
| FarxigaDapagliflozin Propanediol | 43 | $30,795 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 30 | $27,548 |
| JanuviaSitagliptin Phosphate | 34 | $25,409 |
| SynthroidLevothyroxine Sodium | 263 | $18,826 |
| TradjentaLinagliptin | 34 | $18,674 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $18,581 |
| WegovySemaglutide | 14 | $18,576 |
| Repatha SyringeEvolocumab | 19 | $15,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $319,303 | $355,66315 claims |
| Novo NordiskOzempic, Wegovy | $2,266 | $243,474178 claims |
| Lilly USA, LLCMounjaro, Trulicity | $88,864 | $240,343218 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $132,783 | $137,062152 claims |
| AstraZenecaFarxiga | $1,304 | $30,79543 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $541 | $27,54830 claims |
| MerckJanuvia | $236 | $25,40934 claims |
| AbbVieSynthroid | $1,418 | $18,826263 claims |
| Esperion Therapeutics, Inc.Nexletol | $286 | $9,17322 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $423 | $7,179471 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Jackson
- Eric DyessJackson$885K
- Ben SealeJackson$623K
- Amanda SchieferJackson$204K
- John SistrunkJackson$41K
- Raymond GrenfellJackson$16K
- Vanessa SandiferJackson$14K
- John KnightJackson$9K
- Jana PhillipsJackson$8K
- Robert EvansJackson$8K
- Christina GloverJackson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.